PTK2 and osteosarcoma: For example, miR-135a has been described as a tumor suppressor in osteosarcoma pulmonary metastasis by targeting BMI1 and KLF4 [83], and in gastric cancer by downregulating focal adhesion kinase (FAK) pathway, suggesting FAK inhibition as a potential therapeutic strategy [84].